Hellenic Accreditation System

Annex G1/3 to the Certificate No. **1147-1**

SCOPE of ACCREDITATION

of the

Heamatopathology Department

of

EVAGGELISMOS GENERAL HOSPITAL

Materials/Products tested	Types of test/Properties measured	Applied methods/Techniques used
Histochemistry		
Human Body Tissue Formalin Fixed Paraffin Embedded Tissue [FFPE], and Frozen Tissue; Excisional and Incisional Biopsies and Surgical Resection Specimens	Haematoxylin & Eosin stain (H&E)	Myr automated slide strainer. In the case of malfunction, or maintenance, the H&E staining is carried out manually with the same protocol (O.520.02, 1/19-10-2020, E.530-1, 2/19-10-2020)
	Histochemical demonstration of Reticulin fibers	Reticulin stain kit Reticulin Stain: Diapath “silver impregnation”, rev 8_070519 O.520.06, 1/19-10-2020, E.530-1, 2/19-10-2020

Materials/Products tested	Types of test/Properties measured	Applied methods/Techniques used
Immunohistochemistry		
Human Body Tissue Formalin Fixed Paraffin Embedded Tissue [FFPE], and Frozen Tissue; Excisional and Incisional Biopsies And Surgical Resection Specimens (continued)	**Detection of Markers and Protein Expression**	Special staining - IMMUNOHISTOCHEMISTRY: Automated Immunohistochemistry using detection kits DAKO Autostainer Link * Ventana BenchMark XT And antibodies as appropriate: Microscopic Evaluation – Interpretation of Results. Each Antibody E.530-1, 2/19-10-2020
	Anaplastic large cell lymphoma	ALK-1
	T- lymphocytes and B- lymphocytes except GC B-lymphocytes	Bcl2
	GC B- lymphocytes	BCL6
	B- lymphocytes	BOB1
	Hairy Cell Leukemia	BRAF
	GC B-lymphocytes	CD10
	Langerhans cells – Langerhans's cell histiocytosis	CD1a
	Normal and malignant plasma cells	CD138
	Neutrophils, eosinophils, macrophages, R-S cell in Hodgkin lymphoma	CD15
	B- lymphocytes	CD19
	T- lymphocytes	CD2
	B -lymphocytes	CD20
	B- lymphocytes	CD21
	Follicular dendritic cells and a subpopulation of B- lymphocytes	CD23
	T-lymphocytes	CD25
	T-lymphocytes	CD3

Materials/Products tested	Types of test/Properties measured	Applied methods/Techniques used
Immunohistochemistry		
Human Body Tissue Formalin Fixed Paraffin Embedded Tissue [FFPE], and Frozen Tissue; Excisional and Incisional Biopsies And Surgical Resection Specimens (continued)	**Detection of Markers and Protein Expression**	Special staining - IMMUNOHISTOCHEMISTRY: Automated Immunohistochemistry using detection kits DAKO Autostainer Link * Ventana BenchMark XT And antibodies as appropriate: Microscopic Evaluation – Interpretation of Results. Each Antibody E.530-1, 2/19-10-2020
	Activated lymphocytes and plasma cells, R-S cells in Hodgkin lymphoma – Anaplastic large cell lymphoma	CD30
	Monocytes	CD33
	Endothelial cells – blast cells (AML)	CD34
	T helper lymphocytes	CD4
	B-and T-lymphocytes	CD43
	T-lymphocytes and occasionally on a subset of B lymphocytes	CD5
	Neoplastic plasma cells, Neuroendocrine cells/tumors – NK cells	CD56
	Histiocytes, myeloid cells, monocytes	CD68/KP1
	Histiocytes, monocytes	CD68/PGM1
	B-lymphocytes - plasma cells	CD79α
	T -lymphocytes, cytotoxic/ suppressor cells	CD8
	T-lymphocytes, immature blasts	CD99
	Epithelial cells	CK8/18
	Mast cells, GIST	c-kit
	Epithelial cells	CKLowMW
	Macrophages	CMV
	Mantle cell lymphoma, plasma cells,	CyclinD1

Materials/Products tested	Types of test/Properties measured	Applied methods/Techniques used
Immunohistochemistry		
Human Body Tissue Formalin Fixed Paraffin Embedded Tissue [FFPE], and Frozen Tissue; Excisional and Incisional Biopsies And Surgical Resection Specimens (continued)	**Detection of Markers and Protein Expression**	Special staining - IMMUNOHISTOCHEMISTRY: Automated Immunohistochemistry using detection kits DAKO Autostainer Link * Ventana BenchMark XT And antibodies as appropriate: Microscopic Evaluation – Interpretation of Results. Each Antibody E.530-1, 2/19-10-2020
	endothelial cells	
	Epithelial cells	CytoAE1/AE3
	B-lymphocytes	DBA.44
	Erythroid cells	Glycophorin c
	T-lymphocytes(cytotoxic)	Granzyme
	Plasma cells	IgA
	B-lymphocytes (marginal zone plasma cells)	IgD
	Plasma cells	IgG
	Plasma cells	IgM
	Mitotic cell marker	Ki-67
	B-non Hodgkin lymphomas (, HHV8+ Diffuse Large B-cell lymphoma)	LANA1
	B-lymphocytes (GC cells, normal mantle cells)	LMO2
	Monocytes, myeloid cells	Lysozyme
	Mast cells	Mast cell tryptase
	Neutrophil granulocytes and monocytes in blood and precursors of granulocytes in the bone marrow	MPO
	B-lymphocytes, Plasma cells	MUM1
	B-non Hodgkin lymphomas	MYC
	Neuroendocrine cells	NSE
	B-lymphocytes	OCT2
	Dendritic cells in HIV positive	P24

Materials/Products tested	Types of test/Properties measured	Applied methods/Techniques used
Immunohistochemistry		
Human Body Tissue Formalin Fixed Paraffin Embedded Tissue [FFPE], and Frozen Tissue; Excisional and Incisional Biopsies And Surgical Resection Specimens (continued)	**Detection of Markers and Protein Expression**	Special staining - IMMUNOHISTOCHEMISTRY: Automated Immunohistochemistry using detection kits DAKO Autostainer Link * Ventana BenchMark XT And antibodies as appropriate: Microscopic Evaluation – Interpretation of Results. Each Antibody E.530-1, 2/19-10-2020
	B-και T- non Hodgkin Lymphomas	P53
	T-lymphocytes	PanT
	B-lymphocytes	PAX5
	T-lymphocytes	Perforin
	α,β positive T- Cell Receptor)	TcRβ
	γ,δ positive T- Cell Receptor	TcRγ
	B- & T- immature lymphocytes (lymphoblastic leukemia)	TdT
	T-lymphocytes	TIA
	Osteoclasts, B-small cell non Hodgkin lymphomas	TRAP
	Mesenchymal cells, some epithelial cells/tumors	Vimentin
	B-,T-lymphocytes, epithelial cells	EMA
	Kappa positive plasma cells	κ light chain
	Lambda positive plasma cells	λ light chain

** Commercial names mentioned are reffering to specific analytical method and laboratory work protocol.*
WHO: World Health Organizationy
ICD-O: International Classification of Diseases for Oncology
AJCC: American JointCommittee on Cancer
CAP: College of American Pathologists

Site of assessment : **Permanent laboratory premises , Ipsilantou 45-47 Athens**
Approved signatories: **A.Papanikolaou, L. Marinos, G. Kanellis**

The Accreditation Certificate No.**1147**, to ELOT EN ISO/IEC 15189:2012, is valid until 20.11.2027.

Athens, 30.05.2024

Christos Nestoras
CEO of ESYD